Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Lemaitre Vascular (LMAT) over the last 16 years, with Q3 2025 value amounting to $863000.0.

  • Lemaitre Vascular's Asset Writedowns and Impairment rose 105.39% to $863000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 86.33%. This contributed to the annual value of $3.1 million for FY2024, which is 3822.08% up from last year.
  • As of Q3 2025, Lemaitre Vascular's Asset Writedowns and Impairment stood at $863000.0, which was up 105.39% from $393000.0 recorded in Q2 2025.
  • Over the past 5 years, Lemaitre Vascular's Asset Writedowns and Impairment peaked at $1.2 million during Q2 2022, and registered a low of $334000.0 during Q1 2023.
  • In the last 5 years, Lemaitre Vascular's Asset Writedowns and Impairment had a median value of $716000.0 in 2024 and averaged $714368.4.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first skyrocketed by 41275.51% in 2021, then plummeted by 5737.43% in 2023.
  • Quarter analysis of 5 years shows Lemaitre Vascular's Asset Writedowns and Impairment stood at $763000.0 in 2021, then plummeted by 32.9% to $512000.0 in 2022, then soared by 52.73% to $782000.0 in 2023, then increased by 25.06% to $978000.0 in 2024, then dropped by 11.76% to $863000.0 in 2025.
  • Its Asset Writedowns and Impairment was $863000.0 in Q3 2025, compared to $393000.0 in Q2 2025 and $637000.0 in Q1 2025.